REFERENCES

1. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-38.

2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.

3. Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, et al. Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents. Hepatology 2020;71:44-55.

4. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358-80.

5. Dufour JF, Greten TF, Raymond E, Roskams T, De T, et al. Clinical practice guidelines EASL - EORTC clinical practice guidelines: management of hepatocellular carcinoma European Organisation for Research and Treatment of Cancer. J Hepatol 2012;56:908-43.

6. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317-70.

7. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 2016;150:835-53.

8. Colecchia A, Schiumerini R, Cucchetti A, Cescon M, Taddia M, et al. Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol 2014;20:5935-50.

9. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-31.

10. Zhou JY, Zhang L, Li L, Gu GY, Zhou YH, et al. High hepatitis B virus load is associated with hepatocellular carcinomas development in Chinese chronic hepatitis B patients: a case control study. Virol J 2012;9:16.

11. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000;89:500-7.

12. Tung-Ping Poon R, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000;232:10-24.

13. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200-7.

14. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005;25:181-200.

15. Qu LS, Liu JX, Zhu J, Lu CH. Risk factors for prognosis of hepatocellular carcinoma after curative resection in patients with low hepatitis B viral load. Ann Hepatol 2017;16:412-20.

16. Jung KS, Kim JH, Kim SU, Song K, Kim BK, et al. Liver stiffness value-based risk estimation of late recurrence after curative resection of hepatocellular carcinoma: Development and validation of a predictive model. PLoS One 2014;9:e99167.

17. Marasco G, Colecchia A, Colli A, Ravaioli F, Casazza G, et al. Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection. J Hepatol 2019;70:440-8.

18. Yamamoto Y, Ikoma H, Morimura R, Konishi H, Murayama Y, et al. Optimal duration of the early and late recurrence of hepatocellular carcinoma after hepatectomy. World J Gastroenterol 2015;21:1207-15.

19. Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 2009;137:850-5.

20. Pawlik TM, Esnaola NF, Vauthey JN. Surgical treatment of hepatocellular carcinoma: similar long-term results despite geographic variations. Liver Transpl 2004;10:S74-80.

21. Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007;133:481-8.

22. Colecchia A, Colli A, Casazza G, Mandolesi D, Schiumerini R, et al. Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: a prospective study. J Hepatol 2014;60:1158-64.

23. Colecchia A, Marasco G, Taddia M, Montrone L, Eusebi LH, et al. Liver and spleen stiffness and other noninvasive methods to assess portal hypertension in cirrhotic patients: a review of the literature. Eur J Gastroenterol Hepatol 2015;27:992-1001.

24. Colecchia A, Ravaioli F, Marasco G, Festi D. Spleen stiffness by ultrasound elastography. In: Berzigotti A, Bosch J, editors. Diagnostic methods for cirrhosis and portal hypertension. Cham, Springer International Publishing; 2018. pp. 113-37.

25. Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009;50:923-8.

26. Jung KS, Kim SU, Choi GH, Park JY, Park YN, et al. Prediction of recurrence after curative resection of hepatocellular carcinoma using liver stiffness measurement (FibroScan®). Ann Surg Oncol 2012;19:4278-86.

27. Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Tahara M, et al. Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma. World J Surg Oncol 2012;10:107.

28. Liu L, Miao R, Yang H, Lu X, Zhao Y, et al. Prognostic factors after liver resection for hepatocellular carcinoma: a single-center experience from China. Am J Surg 2012;203:741-50.

29. Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IOL, et al. Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transplant 2005;11:1086-92.

30. Colecchia A, Scaioli E, Montrone L, Vestito A, Di Biase AR, et al. Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment. J Hepatol 2011;54:300-5.

31. Pawlik TM, Gleisner AL, Anders RA, Assumpcao L, Maley W, et al. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy. Ann Surg 2007;245:435-42.

32. Jung SM, Kim JM, Choi GS, Kwon CHD, Yi NJ, et al. Characteristics of early recurrence after curative liver resection for solitary hepatocellular carcinoma. J Gastrointest Surg 2019;23:304-11.

33. Lau WY, Sangro B, Chen PJ, Cheng SQ, Chow P, et al. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology 2013;84:311-8.

34. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013;57:1826-37.

35. Hirokawa F, Hayashi M, Miyamoto Y, Asakuma M, Shimizu T, et al. Outcomes and predictors of microvascular invasion of solitary hepatocellular carcinoma. Hepatol Res 2014;44:846-53.

36. Kaibori M, Ishizaki M, Matsui K, Kwon AH. Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma. J Surg Oncol 2010;102:462-8.

37. Rodríguez-Perálvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, et al. A systematic review of microvascular invasion in hepatocellular carcinoma: Diagnostic and prognostic variability. Ann Surg Oncol 2013;20:325-39.

38. Kim JM, Joh JW, Yi NJ, Choi GS, Kim K, et al. Predicting hepatocellular carcinoma recurrence beyond milan criteria after liver resection for solitary hepatocellular carcinoma. J Gastrointest Surg 2019. Epub ahead of print. doi: 10.1007/s11605-019-04363-1

39. Zhao H, Hua Y, Lu Z, Gu S, Zhu L, et al. Prognostic value and preoperative predictors of microvascular invasion in solitary hepatocellular carcinoma ≤ 5 cm without macrovascular invasion. Oncotarget 2017;8:61203-14.

40. Cucchetti A, Cescon M, Ercolani G, Bigonzi E, Torzilli G, et al. A comprehensive meta-regression analysis on outcome of anatomic resection versus nonanatomic resection for hepatocellular carcinoma. Ann Surg Oncol 2012;19:3697-705.

41. Shi M, Guo RP, Lin XJ, Zhang YQ, Chen MS, et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma. Ann Surg 2007;245:36-43.

42. Lai ECS, You KT, Ng IOL, Shek TWH. The pathological basis of resection margin for hepatocellular carcinoma. World J Surg 1993;17:786-90.

43. Tsilimigras DI, Sahara K, Moris D, Hyer JM, Paredes AZ, et al. Effect of surgical margin width on patterns of recurrence among patients undergoing R0 hepatectomy for T1 hepatocellular carcinoma: an international multi-institutional analysis. J Gastrointest Surg 2019. Epub ahead of print. doi: 10.1007/s11605-019-04275-0

44. Belghiti J, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg 1991;214:114-7.

45. Guo Y, Chua DW, Koh YX, Lee SY, Cheow PC, et al. Preoperative predictors including the role of inflammatory indices in predicting early recurrence after re-resection for recurrent hepatocellular carcinoma. World J Surg 2019;43:2587-94.

46. Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 2015;261:947-55.

47. Zhang X, Bai Y, Xu L, Zhang B, Feng S, et al. Clinical and morpho-molecular classifiers for prediction of hepatocellular carcinoma prognosis and recurrence after surgical resection. Hepatol Int 2019;13:715-25.

48. Liao M, Chen P, Liao Y, Li J, Yao W, et al. Preoperative high-sensitivity C-reactive protein to lymphocyte ratio index plays a vital role in the prognosis of hepatocellular carcinoma after surgical resection. Onco Targets Ther 2018;11:5591-600.

49. Hung HC, Lee JC, Cheng CH, Wu TH, Wang YC, et al. Impact of neutrophil to lymphocyte ratio on survival for hepatocellular carcinoma after curative resection. J Hepatobiliary Pancreat Sci 2017;24:559-69.

50. Zheng J, Cai J, Li H, Zeng K, He L, et al. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments: a meta-analysis and systematic review. Cell Physiol Biochem 2017;44:967-81.

51. Itoh S, Yugawa K, Shimokawa M, Yoshiya S, Mano Y, et al. Prognostic significance of inflammatory biomarkers in hepatocellular carcinoma following hepatic resection. BJS Open 2019;3:500-8.

52. Liao M, Qin W, Liao Y, Yao R, Yu J, et al. Prognostic value of gamma-glutamyl transpeptidase to lymphocyte count ratio in patients with single tumor size ≤ 5 cm hepatocellular carcinoma after radical resection. Front Oncol 2019;9:347.

53. Shi S, Chen Q, Ye L, Yin D, Li X, et al. Prognostic value of systemic inflammation score in patients with hepatocellular carcinoma after hepatectomy. Oncotarget 2017;8:79366-75.

54. Wu J, Ma XL, Tian L, Zhang CY, Wang BL, et al. Serum IgG4: IgG ratio predicts recurrence of patients with hepatocellular carcinoma after curative resection. J Cancer 2017;8:1338-46.

55. Chan AWH, Zhong J, Berhane S, Toyoda H, Cucchetti A, et al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol 2018;69:1284-93.

56. Tokumitsu Y, Sakamoto K, Tokuhisa Y, Matsui H, Matsukuma S, et al. A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy. Oncol Lett 2018;15:4411-22.

57. Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavò MR, et al; Rete Sicilia Selezione Terapia - HCV (RESIST-HCV). Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther 2017;46:688-95.

58. Petta S, Cabibbo G, Barbara M, Attardo S, Bucci L, et al. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. Aliment Pharmacol Ther 2017;45:160-8.

59. Singal AG, Rich NE, Mehta N, Branch A, Pillai A, et al. Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study. Gastroenterology 2019;156:1683-92.e1.

60. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.

61. Wu JC, Huang YH, Chau GY, Su CW, Lai CR, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol 2009;51:890-7.

62. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002;155:323-31.

63. Kudo A, Tanaka S, Ban D, Matsumura S, Irie T, et al. Alcohol consumption and recurrence of non-B or non-C hepatocellular carcinoma after hepatectomy: a propensity score analysis. J Gastroenterol 2014;49:1352-61.

64. Bai F, Zhou H, Ma M, Guan C, Lyu J, et al. A novel RNA sequencing-based miRNA signature predicts with recurrence and outcome of hepatocellular carcinoma. Mol Oncol 2018;12:1125-37.

65. Vasuri F, Fittipaldi S, De Pace V, Gramantieri L, Bertuzzo V, et al. Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas. Oncotarget 2018;9:17895-905.

66. Oh J, Lee JM, Park J, Joo I, Yoon JH, et al. Hepatocellular carcinoma: Texture analysis of preoperative computed tomography images can provide markers of tumor grade and disease-free survival. Korean J Radiol 2019;20:569-79.

67. Lee S, Kim SH, Hwang JA, Lee JE, Ha SY. Pre-operative ADC predicts early recurrence of HCC after curative resection. Eur Radiol 2019;29:1003-12.

68. Rimola J, Forner A, Sapena V, Llarch N, Darnell A, et al. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. Eur Radiol 2020;30:186-94.

69. Ahn SJ, Kim JH, Park SJ, Kim ST, Han JK. Hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MR imaging can predict early recurrence after curative resection using image features and texture analysis. Abdom Radiol 2019;44:539-48.

70. Lee S, Kim SH, Lee JE, Sinn DH, Park CK. Preoperative gadoxetic acid–enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma. J Hepatol 2017;67:526-34.

71. Shan Q, Hu H, Feng S, Peng Z, Chen S, et al. CT-based peritumoral radiomics signatures to predict early recurrence in hepatocellular carcinoma after curative tumor resection or ablation. Cancer Imaging 2019;19:11.

72. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, Van Stiphout RGPM, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 2012;48:441-6.

73. Kim S, Shin J, Kim DY, Choi GH, Kim MJ, et al. Radiomics on gadoxetic acid-enhanced magnetic resonance imaging for prediction of postoperative early and late recurrence of single hepatocellular carcinoma. Clin Cancer Res 2019;25:3847-55.

74. Zheng J, Chakraborty J, Chapman WC, Gerst S, Gonen M, et al. Preoperative prediction of microvascular invasion in hepatocellular carcinoma using quantitative image analysis. J Am Coll Surg 2017;225:778-88.e1.

75. Wang J, Shan Q, Liu Y, Yang H, Kuang S, et al. 3D MR elastography of hepatocellular carcinomas as a potential biomarker for predicting tumor recurrence. J Magn Reson Imaging 2019;49:719-30.

76. Fujiwara N, Nakagawa H, Kudo Y, Tateishi R, Taguri M, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol 2015;63:131-40.

77. Lee JI, Lee HW, Kim SU, Ahn SH, Lee KS. Follow-up liver stiffness measurements after liver resection influence oncologic outcomes of hepatitis-b-associated hepatocellular carcinoma with liver cirrhosis. Cancers (Basel) 2019;11:425.

78. Zhang J, Luo Y, Li C, Liu J, Xiang H, et al. The combination of the preoperative albumin-bilirubin grade and the fibrosis-4 index predicts the prognosis of patients with hepatocellular carcinoma after liver resection. Biosci Trends 2019;13:351-7.

79. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, et al. A nssessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach - the albi grade. J Clin Oncol 2015;33:550-8.

80. Lee YH, Koh YS, Hur YH, Cho CK, Kim HJ, et al. Effectiveness of the albumin-bilirubin score as a prognostic factor for early recurrence after curative hepatic resection for hepatocellular carcinoma. Ann Hepato-Biliary-Pancreatic Surg 2018;22:335.

81. Amisaki M, Uchinaka E, Morimoto M, Tokuyasu N, Sakamoto T, et al. Post-operative albumin-bilirubin grade predicts long-term outcomes among Child-Pugh grade A patients with hepatocellular carcinoma after curative resection. Hepatobiliary Pancreat Dis Int 2018;17:502-9.

82. Matsushima H, Takami Y, Ryu T, Yoshitomi M, Tateishi M, et al. Prognosis of hepatocellular carcinoma patients who achieved long-term recurrence-free survival after curative therapy: impact of the ALBI grade. J Gastrointest Surg 2018;22:1230-8.

83. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015;33:550-8.

84. Lin CY, Lin CC, Wang CC, Chen CL, Hu TH, et al. The ALBI grade is a good predictive model for very late recurrence in patients with hepatocellular carcinoma undergoing primary resection. World J Surg 2020;44:247-57.

85. Lin CW, Chen YS, Lin CC, Lee PH, Lo GH, et al. Clinical and translational gastroenterology autophagy-related gene LC3 expression in tumor and liver microenvironments significantly predicts recurrence of hepatocellular carcinoma after surgical resection. Clin Transl Gastroenterol 2018;9:166.

86. Song Q, Chen X, Hu W, Mei G, Yang X, et al. Downregulation of epstein-barr virus-induced gene 3 is associated with poor prognosis of hepatocellular carcinoma after curative resection. Oncol Lett 2018;15:7751-9.

87. Fang Y, He J, Janssen HLA, Wu J, Dong L, et al. Peroxiredoxin 1, restraining cell migration and invasion, is involved in hepatocellular carcinoma recurrence. J Dig Dis 2018;19:155-69.

88. Hoki T, Katsuta E, Yan L, Takabe K, Ito F. Low DMT1 expression associates with increased oxidative phosphorylation and early recurrence in hepatocellular carcinoma. J Surg Res 2019;234:343-52.

89. Chang YY, Yen CJ, Chan SH, Chou YW, Lee YP, et al. NEK2 promotes hepatoma metastasis and serves as biomarker for high recurrence risk after hepatic resection. Ann Hepatol 2018;17:843-56.

90. Ji F, Zhang Z, Zhang Y, Shen SL, Cao QH, et al. Low expression of c-Myc protein predicts poor outcomes in patients with hepatocellular carcinoma after resection. BMC Cancer 2018;18:460.

91. Huang CF, Wang SC, Chang WT, Yeh ML, Huang CI, et al. Lower protein expression levels of MHC class I chain-related gene A in hepatocellular carcinoma are at high risk of recurrence after surgical resection. Sci Rep 2018;8:15821.

92. Lv Y, Wei W, Huang Z, Chen Z, Fang Y, et al. Long non-coding RNA expression profile can predict early recurrence in hepatocellular carcinoma after curative resection. Hepatol Res 2018;48:1140-8.

93. Wang Y, Tan PY, Handoko YA, Sekar K, Shi M, et al. NUF2 is a valuable prognostic biomarker to predict early recurrence of hepatocellular carcinoma after surgical resection. Int J Cancer 2019;145:662-70.

94. Gao XH, Zhang SS, Chen H, Wang K, Xie W, et al. Lipoprotein (A): a promising prognostic biomarker in patients with hepatocellular carcinoma after curative resection. Onco Targets Ther 2018;11:5917-24.

95. Xu Q, Yan Y, Gu S, Mao K, Zhang J, et al. A novel inflammation-based prognostic score: The fibrinogen/albumin ratio predicts prognoses of patients after curative resection for hepatocellular carcinoma. J Immunol Res 2018;2018:4925498.

96. Oh TK, Choi YR, Cho JY, Yoon YS, Han HS, et al. The high-sensitivity C-reactive protein/albumin ratio predicts long-term oncologic outcomes after curative resection for hepatocellular carcinoma. J Clin Med 2018;7:139.

97. Li C, Zhang XY, Peng W, Wen TF, Yan LN, et al. Preoperative albumin-bilirubin grade plus platelet-to-lymphocyte ratio predict the outcomes of patients with BCLC stage A hepatocellular carcinoma after liver resection. Medicine (Baltimore) 2018;97:e11599.

98. Abbate V, Marcantoni M, Giuliante F, Vecchio FM, Gatto I, et al. HepPar1-positive circulating microparticles are increased in subjects with hepatocellular carcinoma and predict early recurrence after liver resection. Int J Mol Sci 2017;18:1043.

99. Aryal B, Yamakuchi M, Shimizu T, Kadono J, Furoi A, et al. Predictive value of diminished serum PDGF-BB after curative resection of hepatocellular cancer. J Oncol 2019;2019:1925315.

100. Liu H, Chen H, Wu X, Sun Y, Wang Y, et al. The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection. Cancer Manag Res 2019;11:2935-46.

101. Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A, et al. Serum WFA+ -M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection. Liver Int 2016;36:293-301.

102. Kim HS, Kim SU, Kim BK, Park JY, Kim DY, et al. Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection. Clin Mol Hepatol 2020;26:33-44.

103. Lee JH, Park JY, Kim DY, Ahn SH, Han KH, et al. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Liver Int 2011;31:1144-9.

104. Cescon M, Colecchia A, Cucchetti A, Peri E, Montrone L, et al. Value of transient elastography measured with fibroscan in predicting the outcome of hepatic resection for hepatocellular carcinoma. Ann Surg 2012;256:706-13.

105. Eguchi S, Kanematsu T, Arii S, Okazaki M, Okita K, et al; Liver Cancer Study Group of Japan. Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery 2008;143:469-75.

106. Xu XF, Xing H, Han J, Li ZL, Lau WY, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. In: JAMA Surg 2019;154:209-17.

107. Chan EEH, Chow PKH. A review of prognostic scores after liver resection in hepatocellular carcinoma: the MSKCC, SLICER and SSCLIP scores. Jpn J Clin Oncol 2016;47:287-93.

108. Testino G, Leone S, Borro P. Alcohol and hepatocellular carcinoma: a review and a point of view. World J Gastroenterol 2014;20:15943-54.

109. Shinkawa H, Tanaka S, Takemura S, Ito T, Aota T, et al. Obesity and recurrence-free survival in patients with hepatocellular carcinoma after achieving sustained virological response to interferon therapy for chronic hepatitis C. Ann Gastroenterol Surg 2018;2:319-26.

110. Qin W, Wang L, Hu B, Leng S, Tian H, et al. A novel score predicts HBV-related hepatocellular carcinoma recurrence after hepatectomy: a retrospective multicenter study. J Gastrointest Surg 2019;23:922-32.

111. Colecchia A, Montrone L, Scaioli E, Bacchi-Reggiani ML, Colli A, et al. Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology 2012;143:646-54.

112. Festi D, Dajti E, Ravaioli F, Marasco G, Colecchia A. Role and clinical meaning of non-invasive tests in the evaluation of portal hypertension in patients with advanced chronic liver disease. Recenti Prog Med 2018;109:574-84.

113. Marasco G, Colecchia A, Dajti E, Ravaioli F, Cucchetti A, et al. Prediction of posthepatectomy liver failure: role of SSM and LSPS. J Surg Oncol 2019;119:400-1.

114. Korean Liver Cancer Association (KLCA); National Cancer Center (NCC). 2018 Korean liver cancer association-national cancer center korea practice guidelines for the management of hepatocellular carcinoma. Korean J Radiol 2019;20:1042-113.

115. Livraghi T, Festi D, Monti F, Salmi A, Vettori C. US-guided percutaneous alcohol injection of small hepatic and abdominal tumors. Radiology 1986;161:309-12.

116. Shiina S, Tateishi R, Imamura M, Teratani T, Koike Y, et al. Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors. Liver Int 2012;32:1434-42.

117. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.

118. Khan KN, Yatsuhashi H, Yamasaki K, Yamasaki M, Inoue O, et al. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. J Hepatol 2000;32:269-78.

119. Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgrò G, et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol 2010;52:380-8.

120. Ebara M, Okabe S, Kita K, Sugiura N, Fukuda H, et al. Percutaneous ethanol injection for small hepatocellular carcinoma: Therapeutic efficacy based on 20-year observation. J Hepatol 2005;43:458-64.

121. Koda M, Murawaki Y, Mitsuda A, Ohyama K, Horie Y, et al. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer 2000;88:529-37.

122. Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 1998;27:67-72.

123. Shiina S, Tagawa K, Unuma T, Takanashi R, Yoshiura K, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma. a histopathologic study. Cancer 1991;68:1524-30.

124. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤ 4 cm. Gastroenterology 2004;127:1714-23.

125. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005;54:1151-6.

126. Hines-Peralta A, Liu ZJ, Horkan C, Solazzo S, Goldberg SN. Chemical tumor ablation with use of a novel multiple-tine infusion system in a canine sarcoma model. J Vasc Interv Radiol 2006;17:351-8.

127. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 2008;47:82-9.

128. Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology 2012;262:43-58.

129. Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, et al. Treatment strategies for hepatocellular carcinoma - a multidisciplinary approach. Int J Mol Sci 2019;20:1465.

130. Ganne-Carrié N, Nault JC, Ziol M, N’Kontchou G, Nahon P, et al. Predicting recurrence following radiofrequency percutaneous ablation for hepatocellular carcinoma. Hepatic Oncol 2014;1:395-408.

131. Zytoon AA, Ishii H, Murakami K, El-kholy MR, Furuse J, et al. Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome. Jpn J Clin Oncol 2007;37:658-72.

132. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127:S179-88.

133. Sandow TA, Arndt SE, Albar AA, DeVun DA, Kirsch DS, et al. Assessment of response to transcatheter arterial chemoembolization with doxorubicin-eluting microspheres: tumor biology and hepatocellular carcinoma recurrence in a 5-year transplant cohort. Radiology 2018;286:1072-83.

134. Yamakado K, Takaki H, Nakatsuka A, Yamaknaka T, Fujimori M, et al. Radiofrequency ablation for hepatocellular carcinoma. Gastrointest Interv 2014;3:35-9.

135. Poon RTP, Lau C, Yu WC, Fan ST, Wong J. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep 2004;11:1077-84.

136. Liao X, Yi J, Li X, Yang Z, Deng W, et al. Expression of angiogenic factors in hepatocellular carcinoma after transcatheter arterial chemoembolization. J Huazhong Univ Sci Technolog Med Sci 2003;23:280-2.

137. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, et al. TTranscatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008;103:914-21.

138. Xuan ZD, Zhou L, Wang Y, Zheng X. Prognostic value of the combination of serum levels of vascular endothelial growth factor, C-reactive protein and contrast-enhanced ultrasound in patients with primary liver cancer who underwent transcatheter arterial chemoembolization. Expert Rev Anticancer Ther 2017;17:1169-78.

139. Katyal S, Oliver JH, Peterson MS, Chang PJ, Baron RL, et al. Prognostic significance of arterial phase CT for prediction of response to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: a retrospective analysis. Am J Roentgenol 2000;175:1665-72.

140. Lee YK, Kim SU, Kim DY, Ahn SH, Lee KH, et al. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer 2013;13:5.

141. Kim BK, Ahn SH, Seong JS, Park JY, Kim DY, et al. Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. Liver Int 2011;31:369-76.

142. Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 2009;27:5734-42.

143. Yang Z, Zhang J, Lu Y, Xu Q, Tang B, et al. Aspartate aminotransferase-lymphocyte ratio index and systemic immune-inflammation index predict overall survival in HBV-related hepatocellular carcinoma patients after transcatheter arterial chemoembolizations. Oncotarget 2015;6:43090-8.

144. Shen Y, Wang H, Li W, Chen J. Prognostic significance of the CRP/Alb and neutrophil to lymphocyte ratios in hepatocellular carcinoma patients undergoing TACE and RFA. J Clin Lab Anal 2019;33:e22999.

145. Cai XR, Chen ZH, Liu MM, Lin JX, Zhang XP, et al. Modified CLIP score with the albumin-bilirubin grade retains prognostic value in HBV-related hepatocellular carcinoma patients treated with trans-catheter arterial chemoembolization therapy. J Cancer 2018;9:2380-8.

146. Kim JH, Sinn DH, Lee JH, Hyun D, Cho SK, et al. Novel albumin–bilirubin grade-based risk prediction model for patients with hepatocellular carcinoma undergoing chemoembolization. Dig Dis Sci 2018;63:1062-71.

147. Chung GE, Kim W, Lee JH, Kim YJ, Yoon JH, et al. Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy. J Gastroenterol Hepatol 2011;26:1638-45.

148. Sohn W, Paik YH, Lee MW, Rhim H, Lim HK, et al. Predisposing factors for recurrence of HBV-related small hepatocellular carcinoma after percutaneous radiofrequency ablation. Scand J Gastroenterol 2014;49:373-80.

149. Kim SS, Nam JS, Cho HJ, Won JH, Kim JW, et al. Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2017;32:199-207.

150. Cui L, Hu Y, Bai B, Zhang S. Serum miR-335 level is associated with the treatment response to trans-arterial chemoembolization and prognosis in patients with hepatocellular carcinoma. Cell Physiol Biochem 2015;37:276-83.

151. Lu YL, Yao JG, Huang XY, Wang C, Wu XM, et al. Prognostic significance of miR-1268a expression and its beneficial effects for post-operative adjuvant transarterial chemoembolization in hepatocellular carcinoma. Sci Rep 2016;6:36104.

152. Ali HEA, Emam AA, Zeeneldin AA, Srour R, Tabashy R, et al. Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization. Clin Biochem 2019;65:45-52.

153. Gao Y, Zheng DY, Cui Z, Ma Y, Liu YZ, et al. Predictive value of quantitative contrast-enhanced ultrasound in hepatocellular carcinoma recurrence after ablation. World J Gastroenterol 2015;21:10418-26.

154. Kim SH, Lee WJ, Lim HK, Lim JH. Prediction of viable tumor in hepatocellular carcinoma treated with transcatheter arterial chemoembolization: usefulness of attenuation value measurement at quadruple-phase helical computed tomography. J Comput Assist Tomogr 2007;31:198-203.

155. Kokabi N, Ludwig JM, Camacho JC, Xing M, Mittal PK, et al. Baseline and early MR apparent diffusion coefficient quantification as a predictor of response of unresectable hepatocellular carcinoma to doxorubicin drug-eluting bead chemoembolization. J Vasc Interv Radiol 2015;26:1777-86.

156. Kim HC, Kim AY, Han JK, Chung JW, Lee JY, et al. Hepatic arterial and portal venous phase helical CT in patients treated with transcatheter arterial chemoembolization for hepatocellular carcinoma: added value of unenhanced images. Radiology 2002;225:773-80.

157. Ebied OM, Federle MP, Carr BI, Pealer KM, Li W, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 2003;97:1042-50.

158. Park HJ, Kim JH, Choi SY, Lee ES, Park SJ, et al. Prediction of therapeutic response of hepatocellular carcinoma to transcatheter arterial chemoembolization based on pretherapeutic dynamic CT and textural findings. Am J Roentgenol 2017;209:W211-20.

159. Maesaka K, Sakamori R, Yamada R, Tahata Y, Urabe A, et al. Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma. Hepatol Res 2020;50:365-73.

160. Choi SJ, Kim J, Seo J, Kim HS, Lee JM, et al. Parametric response mapping of dynamic CT as an imaging biomarker to distinguish viability of hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Abdom Imaging 2014;39:518-25.

161. Huppertz A, Haralda S, Kraus A, Zech CJ, Scheidler J, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005;234:468-78.

162. Ishimaru H, Nakashima K, Sakugawa T, Sakamoto A, Matsuoka Y, et al. Local recurrence after chemoembolization of hepatocellular carcinoma: uptake of gadoxetic acid as a new prognostic factor. Am J Roentgenol 2014;202:744-51.

163. Ou HY, Cheng YF, Chuang YH, Hsu HW, Chen CL, et al. Quantification of functional MR predicts early response in post-doxorubicin drug-eluting beads chemoembolization for hepatocellular carcinoma. Dig Dis Sci 2019. Epub ahead of print. doi: 10.1007/s10620-019-05951-6

164. Kobayashi T, Kawai H, Nakano O, Abe S, Kamimura H, et al. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies. BMC Cancer 2018;18:756.

165. Eggert T, Greten TF. Current standard and future perspectives in non-surgical therapy for hepatocellular carcinoma. Digestion 2017;96:1-4.

166. Minami Y. Radiofrequency ablation of hepatocellular carcinoma: current status. World J Radiol 2010;2:417.

167. Lau WY, Lai ECH. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg 2009;249:20-5.

168. Na BG, Kim JM, Oh DK, Lee KW, Kang TW, et al. Clinical outcomes of laparoscopic radiofrequency ablation of single primary or recurrent hepatocellular carcinoma (≤ 3 cm). Ann Surg Treat Res 2017;92:355-60.

169. Lencioni R, Cioni D, Crocetti L, Franchini C, Della Pina C, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: Long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005;234:961-7.

170. Nault JC, Sutter O, Nahon P, Ganne-Carrié N, Séror O. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. J Hepatol 2018;68:783-97.

171. Toshimori J, Nouso K, Nakamura S, Wada N, Morimoto Y, et al. Local recurrence and complications after percutaneous radiofrequency ablation of hepatocellular carcinoma: a retrospective cohort study focused on tumor location. Acta Med Okayama 2015;69:205-12.

172. Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg 2011;98:1210-24.

173. Sparchez Z, Mocan T, Radu P, Mocan LP, Sparchez M, et al. Prognostic factors after percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma. Impact of incomplete ablation on recurrence and overall survival rates. J Gastrointest Liver Dis 2018;27:399-407.

174. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 2012;308:1906-13.

175. N’Kontchou G, Mahamoudi A, Aout M, Ganne-Carrié N, Grando V, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 western patients with cirrhosis. Hepatology 2009;50:1475-83.

176. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015;63:237-64.

177. Rekik S, Allaire M, Mumana A, Guyot E, Nkontchou G, et al. Transient elastography predicts survival after radiofrequency ablation of hepatocellular carcinoma developing on cirrhosis. J Gastroenterol Hepatol 2020;35:142-50.

178. Llovet JM, Real MI, Montaña X, Planas R, Coll S, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9.

179. Kong J, Li S, Fan H, Zhang L, Zhao H, et al. Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma. Medicine (Baltimore) 2018;97:e11872.

180. Liapi E, Georgiades CC, Hong K, Geschwind JFH. Transcatheter arterial chemoembolization: current technique and future promise. Tech Vasc Interv Radiol 2007;10:2-11.

181. Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol 2015;62:1187-95.

182. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, et al. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin Drug Eluting Beads (DEB) for unresectable Hepatocelluar Carcinoma (HCC). J Surg Oncol 2010;101:476-80.

183. Poon RTP, Tso WK, Pang RWC, Ng KKC, Woo R, et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007;5:1100-8.

184. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998;28:68-77.

185. Ogasawara S, Yano H, Iemura A, Hisaka T, Kojiro M. Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines. Hepatology 1996;24:198-205.

186. Zhu CB, Wang C, Chen LL, Ma GL, Zhang SC, et al. Serum YKL-40 independently predicts outcome after transcatheter arterial chemoembolization of hepatocellular carcinoma. PLoS One 2012;7:e44648.

187. Casadei Gardini A, Conti F, Foschi FG, Brillanti S, Andreone P, et al. Imbalance of neutrophils and lymphocyte counts can be predictive of hepatocellular carcinoma occurrence in hepatitis C-related cirrhosis treated with direct-acting antivirals. Gastroenterology 2018;154:2281-2.

188. Casadei Gardini A, Foschi FG, Conti F, Petracci E, Vukotic R, et al. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. Dig Liver Dis 2019;51:681-8.

189. Wang B, Li F, Cheng L, Zhan Y, Wu B, et al. The pretreatment platelet count is an independent predictor of tumor progression in patients undergoing transcatheter arterial chemoembolization with hepatitis B virus-related hepatocellular carcinoma. Futur Oncol 2019;15:827-39.

190. Wu YQ, Fan WZ, Xue M, Guo J, Wei JL, et al. 25-OH-vitamin D deficiency identifies poor tumor response in hepatocellular carcinoma treated with transarterial chemoembolization. Clin Transl Oncol 2020;22:70-80.

191. Zhang JB, Chen Y, Zhang B, Xie X, Zhang L, et al. Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol 2011;23:787-93.

192. Shen H, Zheng S, Chen R, Jin X, Xu X, et al. Prognostic significance of serum procalcitonin in patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Medicine (Baltimore) 2017;96:e7438.

193. Liu PH, Hsu CY, Hsia CY, Lee YH, Su CW, et al. Prognosis of hepatocellular carcinoma: assessment of eleven staging systems. J Hepatol 2016;64:601-8.

194. Biselli M, Andreone P, Gramenzi A, Trevisani F, Cursaro C, et al. Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study. Clin Gastroenterol Hepatol 2005;3:918-25.

195. Brown DB, Fundakowski CE, Lisker-Melman M, Crippin JS, Pilgram TK, et al. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2004;15:1209-18.

196. Testa R, Testa E, Giannini E, Botta F, Malfatti F, et al. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: Role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatm. Aliment Pharmacol Ther 2003;17:1563-9.

197. Xu L, Peng ZW, Chen MS, Shi M, Zhang YJ, et al. Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. J Hepatol 2015;63:122-30.

198. Sasaki R, Taura N, Miyazoe Y, Yamamichi S, Nakashiki S, et al. Ketone bodies as a predictor of prognosis of hepatocellular carcinoma after transcatheter arterial chemoembolization. Nutrition 2018;50:97-103.

199. Yu X, Ge N, Guo X, Shen S, Liang J, et al. Genetic variants in the EPCAM gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma with portal vein tumor thrombus. PLoS One 2014;9:e93416.

200. Hu W, Huang S, Dong L, Yu C, Li C, et al. MDR1 gene polymorphism correlated with pathological characteristics and prognosis in patients with primary hepatocellular carcinoma receiving interventional therapy. Anticancer Drugs 2019;30:233-40.

201. Zhang H, Guo X, Dai J, Wu Y, Ge N, et al. Genetic variations in IDH gene as prognosis predictors in TACE-treated hepatocellular carcinoma patients. Med Oncol 2014;31:1-8.

202. Liang KH, Lin CL, Chen SF, Chiu CW, Yang PC, et al. GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Pharmacogenomics 2016;17:353-66.

203. Wang G, Bi C. Correlations of pri-Let-7 gene polymorphisms with the recurrence and metastasis of primary liver cancer after transcatheter arterial chemoembolization. Pathol Res Pract 2018;214:667-72.

204. Fako V, Martin SP, Pomyen Y, Budhu A, Chaisaingmongkol J, et al. Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization. Int J Biol Sci 2019;15:2654-63.

205. Spârchez Z, Mocan T, Radu P, Anton O, Comsa M, et al. Contrast enhanced ultrasonography in assessing the treatment response to transarterial chemoembolization in patients with hepatocellular carcinoma. Med Ultrason 2016;18:96-102.

206. Sung SA, Kim MJ, Joon SL, Hong HS, Yong EC, et al. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010;255:459-66.

207. Hwang J, Kim SH, Kim YS, Lee MW, Woo JY, et al. Gadoxetic acid-enhanced MRI versus multiphase multidetector row computed tomography for evaluating the viable tumor of hepatocellular carcinomas treated with image-guided tumor therapy. J Magn Reson Imaging 2010;32:629-38.

208. Tacher V, Lin M, Duran R, Yarmohammadi H, Lee H, et al. Comparison of existing response criteria in patients with hepatocellular carcinoma treated with transarterial chemoembolization using a 3D quantitative approach. Radiology 2016;278:275-84.

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/